CNSP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.7M
-45.7%
5.0M
-16.9%
6.0M
+84.0%
3.3M
+35.1%
2.4M
R&D
1.2M
-66.1%
3.5M
+12.0%
3.2M
+44.1%
2.2M
+88.2%
1.2M
SG&A
1.5M
+4.7%
1.4M
-49.3%
2.8M
+167.0%
1.1M
-14.9%
1.2M
Operating Income
-2700000
+45.7%
-4975205
+16.9%
-5986126
-84.0%
-3253388
-35.1%
-2409000
EBITDA
-2688868
+45.9%
-4973337
+16.9%
-5985106
-84.0%
-3252691
-35.1%
-2408100
Net Income
-2588000
+47.6%
-4937046
+17.1%
-5955802
-85.1%
-3218481
-35.5%
-2375000
EPS (Basic)
$-0.38
+94.8%
$-7.30
+24.4%
$-9.65
-67.5%
$-5.76
+10.3%
$-6.42
EPS (Diluted)
$-0.38
+94.8%
$-7.30
+24.4%
$-9.65
-67.5%
$-5.76
+10.3%
$-6.42
Shares (Diluted)
6.8M
+911.3%
676.2K
+9.5%
617.3K
+10.4%
558.9K
+51.0%
370.1K
CNS Pharmaceuticals (CNSP) — Financials